This will allow quick identification of new safety information Healthcare professionals are asked to report any suspected adverse reactions See section 4.8 for how to report adverse reactions Name of the medicinal product Ritlecitinib is currently licensed to treat severe alopecia areata in adults and young people aged 12 years and older Why have i been selected for treatment with ritlecitinib
The health professional caring for you will have assessed the extent of your hair loss and how it is affecting you. Ritlecitinib was not mutagenic in the bacterial mutagenicity assay (ames assay) Ritlecitinib is not aneugenic or clastogenic at exposures equal to 130 times the mrhd on an unbound auc basis based on the results of the in vivo rat bone marrow micronucleus assay. Ritlecitinib should be used with caution in patients with known risk factors for thromboembolism When taking ritlecitinib, it is currently not recommended to take other medicines that suppress the immune system, as these have not been studied If you have you have an intolerance to lactose, contact your health professional before taking this medicine as ritlecitinib contains lactose
Ritlecitinib costs £949.41 per pack of 30 capsules (dictionary of medicines and devices, accessed february 2024) The company has a commercial arrangement This makes ritlecitinib available to the nhs with a discount The size of the discount is commercial in confidence. Ritlecitinib is recommended, within its marketing authorisation, as an option for treating severe alopecia areata in people 12 years and over in line with nice ta958 Ritlecitinib is only recommended if the company provides it according to the commercial arrangement.
The active substance in litfulo, ritlecitinib, is an immunosuppressant (a medicine that reduces the activity of the immune system) It works by blocking the action of certain enzymes called jak3 and tec kinases, which play an important role in inflammation.
OPEN
